Cowen & Co. initiated coverage on Nautilus Biotechnology
$NAUT
Biotechnology: Laboratory Analytical Instruments
Industrials
Cowen & Co. initiated coverage of Nautilus Biotechnology with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/5/2024 | $1.75 | Neutral → Sell | Goldman |
| 6/27/2024 | $6.00 | Buy | Guggenheim |
| 6/3/2024 | $3.00 | Hold | Jefferies |
| 1/6/2022 | $8.00 | Equal-Weight | Morgan Stanley |
| 11/2/2021 | Outperform | Cowen & Co. | |
| 8/4/2021 | $10.00 | Neutral | Goldman Sachs |
| 7/13/2021 | $13.00 | Buy | Jefferies |
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)
SCHEDULE 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter 2026 before market open on Tuesday, July 28, 2026. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its
SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Business Highlights Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.Appointed Amber Faust as Vice President of Global Sale
SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter 2026 before market open on Tuesday, April 28, 2026. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)
Goldman downgraded Nautilus Biotechnology from Neutral to Sell and set a new price target of $1.75
Guggenheim initiated coverage of Nautilus Biotechnology with a rating of Buy and set a new price target of $6.00
Jefferies resumed coverage of Nautilus Biotechnology with a rating of Hold and set a new price target of $3.00
SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)
SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering single-molecule proteome analysis, today announced the appointment of Amber Faust as Vice President of Sales. Ms. Faust joins Nautilus following the public debut of the Nautilus Voyager™ Platform, designed to deliver and scale Iterative Mapping, a method that enables single-molecule analysis of proteins and proteoforms across the proteome. Ms. Faust brings nearly two decades of commercial leadership experience in life sciences, with a focus on advancing adoption of emerging proteomics technologies across pharmaceutical, biotechnology, academic, clinical, and government sectors. S
SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Nautilus after 25 years in product and marketing leadership roles at Agilent Technologies, most recently serving as Vice President and General Manager of Agilent's Mass Spectrometry division. He has held numerous leadership positions at Agilent, including in the Strategic Program Office and Certified Pre-Owned Instruments, CrossLab Services and Support, and Spectroscopy. "Ke
SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development. Dr. Huber brings to Nautilus over 20 years of experience in biotechnology start-ups both in Europe and the US, most recently as founder, CTO and, ultimately, CEO of Quantapore, a company devoted to pioneering massively parallel, direct, single-molecule DNA and protein analytical tools. Prior to that, he he
SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter 2026 before market open on Tuesday, July 28, 2026. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its
SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Business Highlights Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.Appointed Amber Faust as Vice President of Global Sale
SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter 2026 before market open on Tuesday, April 28, 2026. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its